PET Scan in Treating Patients With Metastatic Prostate Cancer
Prostate Cancer
About this trial
This is an interventional diagnostic trial for Prostate Cancer focused on measuring adenocarcinoma of the prostate, stage IV prostate cancer, recurrent prostate cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed prostate adenocarcinoma Must have an at least 50% increase in PSA which is sustained for a minimum of 3 observations obtained at least 1 week apart Must have development of new lesions on bone scintigraphy or greater than 50% increase in measurable disease on CT or MRI scan Metastatic disease PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky greater than 60% Hematopoietic: ANC greater than 1,000/mm^3 Platelet count greater than 100,000/mm^3 Hepatic: Not specified Renal: Not specified Cardiovascular: No clinically significant cardiac disease Pulmonary: No clinically significant pulmonary disease Other: No active infection not controlled by antibiotics PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified
Sites / Locations
- Memorial Sloan Kettering Cancer Center
Arms of the Study
Arm 1
Experimental
PET Scan
Each patient receives C11-methionine intravenously. PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures. Immediately following the completion of imaging after C11-methionine administration, each patient receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures.